IDEAYA Biosciences, Inc.
NASDAQ:IDYABiotechnology
-$0.45 today
- Market cap
- $2.56B
- Beta
- -0.05
- P/E (TTM)
- -19.5
- EPS (TTM)
- -$1.58
Volume 1.45M
Average 1.44M
IDYA Total Current Liabilities
All obligations due within one year.
IDEAYA Biosciences, Inc.NASDAQ: IDYA
Total Current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total current liabilities rises 27.5% from a year ago
Total current liabilities stood at $64.83M at the end of Q1 FY2026, up 27.5% from a year earlier and up 10.2% from the prior quarter. Over 3 fiscal years it compounded at +22.9% a year.
Context
- Total current liabilities amounted to 6.3% of total assets at the end of Q1 FY2026, up 1.7 pp from a year earlier.
- Total current liabilities increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total current liabilities keeps rising in the next quarterly balance sheet after a +27.5% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 58.82M USD
- Year-over-year change
- +27.7%
- 4-year CAGR
- +6.8%
| Period | Period end | Total Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 58.82M | +27.7% |
| FY2024 | 2024-12-31 | 46.07M | +70.0% |
| FY2023 | 2023-12-31 | 27.1M | -14.6% |
| FY2022 | 2022-12-31 | 31.72M | -29.8% |
| FY2021 | 2021-12-31 | 45.16M | — |
Total Current Liabilities vs competitors
How IDYA compares with its peers on the latest reported figures
- IDYA's Mar 2026 total current liabilities of $64.83M is the 4th highest of the 9 companies compared; the peer median is $61.85M.
- Its year-over-year change of +27.5% is the 7th highest of 9, against a peer median of +56.0%.
- Total current liabilities amounts to 6.3% of total assets for IDYA, versus a peer median of 9.6%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $354.06M | +91.9% | +67.3% | 8.2% | |
| Aug 2026 | $130.74M | +58.8% | +7.0% | 10.9% | |
| Mar 2026 | $66.85M | +87.7% | +49.4% | 29.3% | |
| Mar 2026 | $64.83M | +27.5% | +22.9% | 6.3% | |
| Mar 2026 | $64.4M | -9.7% | +2.7% | 29.0% | |
| Jun 2026 | $59.3M | +1.5% | +33.6% | 7.1% | |
| Sep 2026 | $43.99M | +53.2% | -16.3% | 4.4% | |
| Mar 2026 | $41.72M | +110.8% | +34.7% | 34.9% | |
| Sep 2026 | $25.16M | +36.4% | -26.9% | 2.4% | |
| Peer median (excluding IDYA) | $61.85M | +56.0% | +20.3% | 9.6% | |
Competitors are the stored peer set for IDYA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 92.05M | 68.63M | 157.02M | 84.38M | 112.83M |
| Short-term Investments | 154.72M | 296.2M | 368.1M | 591.94M | 526.56M |
| Net Receivables | 1.1M | 211K | 18K | 3K | 5.97M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 5.41M | 7.5M | 13.39M | 21.37M |
| Total Current Assets | 251M | 370.45M | 532.63M | 689.71M | 666.73M |
| Property, Plant & Equipment (Net) | 8.66M | 8.99M | 8.41M | 27.74M | 31.29M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 121.29M | 8.32M | 107.49M | 405.83M | 410.3M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 397K | 205K | 782K | 805K | 1.02M |
| Total Non-current Assets | 130.35M | 17.52M | 116.68M | 434.38M | 442.6M |
| Total Assets | 381.35M | 387.97M | 649.32M | 1.12B | 1.11B |
| Account Payables | 2.1M | 4.28M | 6.6M | 15.42M | 17.58M |
| Short-term Debt | 0 | 0 | 0 | 0 | 339K |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 29.04M | 8.57M | 0 | 0 | 0 |
| Other Current Liabilities | 0 | 0 | 11.78M | 30.35M | 29.69M |
| Total Current Liabilities | 45.16M | 31.72M | 27.1M | 46.07M | 58.82M |
| Long-term Debt | 0 | 0 | 0 | 0 | 27.58M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 31.19M | 5.19M | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 0 | 0 | 0 | 0 |
| Total Non-current Liabilities | 34.67M | 6.8M | 1.13M | 18.87M | 27.58M |
| Total Liabilities | 79.83M | 38.51M | 28.23M | 64.94M | 86.39M |
| Common Stock | 4K | 5K | 7K | 9K | 9K |
| Retained Earnings | (176.75M) | (235.4M) | (348.36M) | (622.84M) | (736.54M) |
| Accumulated OCI | (712K) | (2.87M) | 562K | 812K | 2.27M |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 301.51M | 349.46M | 621.09M | 1.06B | 1.02B |
| Total Debt | 5.18M | 3.48M | 2.87M | 19.17M | 27.91M |
| Net Debt | (86.87M) | (65.15M) | (154.15M) | (65.21M) | (84.91M) |
IDEAYA Biosciences, Inc.
NASDAQ:IDYA
Intrinsic Alpha fair value
Locked
Current Price
$26.49
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.